A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab

Roche

Status: Completed

Conditions: Metastatic Colorectal Cancer

Treatments: Other: No intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02673710

ML29985

Details and patient eligibility

About

The purpose of this study is to explore the relationship between sarcopenia, as defined by computed tomography, treatment related outcomes and other body composition related parameters in a patient population receiving bevacizumab beyond progression.

Enrollment: 200 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients treated in first line with bevacizumab for whom it is decided, and who are clinically considered eligible, to continue the treatment with bevacizumab beyond PD1.
• Women of childbearing potential have to use effective contraception during (and up to 6 months after) treatment.
• Availability of specific retrospective data at diagnosis and during 1st line treatment

Exclusion criteria

• Patients who are participating or participated in first line in any other interventional clinical trial involving non-standard of care procedures impacting the body composition
• Dementia or another mental condition making it impossible to fill out questionnaires

Trial design

200 participants in 1 patient group

Participants with metastatic colorectal cancer

Description:

Participants diagnosed with mCRC treated in first line with a combination of bevacizumab and chemotherapy for whom it is decided to continue the administration of bevacizumab beyond progression while changing CTR will be included in this study

Treatment:

Other: No intervention